Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C-type lectin domain family 13 member A (CD302)
- Target
- CD302
- Molecular classification
- Receptor, C-type lectin receptor, Transmembrane protein, Carbohydrate-binding protein
01
Overview
CD302 (C-type lectin domain family 13 member A; CD302 antigen) is a single-pass type I transmembrane C-type lectin receptor expressed in liver cells, monocytes, dendritic cells, and other tissues[7][8]. Its protein consists of a C-type lectin domain that binds carbohydrates in a calcium-dependent manner[3][9][10]. CD302 contributes to cellular adhesion, migration, and immune surveillance by enabling phagocytosis and endocytosis, especially in antigen-presenting cells. In the liver, CD302 mediates intrinsic antiviral defense by restricting hepatitis C virus entry, though it does not impact downstream nuclear receptor gene signaling[1]. Its expression and function are being studied for cancer cell migration and in broader models of infection and immunity. No approved drugs currently target CD302 directly; ongoing research suggests it may be a valuable therapeutic target in antiviral and anticancer strategies.
- Other names
- CD302 moleculeCD302 antigenCLEC13ADCL1DCL-1KIAA0022BIMLECC-type lectin BIMLECDEC205-associated C-type lectin 1Type I transmembrane C-type lectin receptor DCL-1
02
Mechanism of action
Not applicable (as no drugs are approved to act via CD302; in research, modulation of viral entry and immune cell migration are observed)
03
Biological functions
Cell adhesionCell migrationEndocytosisPhagocytosisAntigen uptake and presentationIntrinsic antiviral defense (notably against hepatitis C virus)
04
Disease associations
Infection (notably hepatitis C virus restriction)Cancer (studied in cancer cell migration and function)Inflammation (given expression in immune cells)
05
Safety considerations
Potential immunological challenges due to its expression in both immune and liver cells, but no specific therapy-related safety concerns detected in search results
Beyond the preview
Go deeper on C-type lectin domain family 13 member A (CD302).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C-type lectin domain family 13 member A (CD302).